Allarity Therapeutics (NASDAQ:ALLR) Upgraded at Wall Street Zen

Allarity Therapeutics (NASDAQ:ALLR) was upgraded by equities research analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

Separately, Ascendiant Capital Markets started coverage on Allarity Therapeutics in a research report on Monday, July 28th. They issued a “buy” rating and a $9.00 price objective for the company. One analyst has rated the stock with a Buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $9.00.

Allarity Therapeutics Price Performance

Shares of NASDAQ ALLR opened at $1.54 on Friday. The business has a fifty day moving average of $1.25 and a two-hundred day moving average of $1.06. Allarity Therapeutics has a 52-week low of $0.61 and a 52-week high of $2.40.

Allarity Therapeutics (NASDAQ:ALLR) last released its quarterly earnings results on Friday, August 15th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.06. As a group, equities analysts forecast that Allarity Therapeutics will post -78.08 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Allarity Therapeutics

A number of large investors have recently added to or reduced their stakes in the business. XTX Topco Ltd bought a new position in Allarity Therapeutics during the 2nd quarter worth $51,000. Geode Capital Management LLC boosted its stake in shares of Allarity Therapeutics by 49.3% during the second quarter. Geode Capital Management LLC now owns 50,650 shares of the company’s stock valued at $51,000 after purchasing an additional 16,729 shares in the last quarter. Finally, Jane Street Group LLC acquired a new stake in shares of Allarity Therapeutics during the second quarter valued at about $27,000. Institutional investors own 11.53% of the company’s stock.

About Allarity Therapeutics

Allarity Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA (ixabepilone), a selective microtubule inhibitor in phase 2 for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme.